Physician profile
Charles E Gaba
NPI 1801866025
$11,299.21
in general payments reported to CMS, 2019-2025
48 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,701 · 2020: $1,206 · 2021: $2,058 · 2022: $1,571 · 2023: $1,733 · 2024: $1,696 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,351.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,200.10 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $1,058.20 | 2019-2025 | |
| Novo Nordisk INC | $910.65 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $854.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.39 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $815.66 | 2019-2025 | |
| Lilly USA, LLC | $574.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $404.29 | 2019-2022 | |
| Esperion Therapeutics, INC. | $372.25 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $343.38 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $302.28 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $211.50 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $208.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $175.95 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.